Last reviewed · How we verify
Pegylated interferon alfa-2a plus ribavarin
At a glance
| Generic name | Pegylated interferon alfa-2a plus ribavarin |
|---|---|
| Also known as | Pegasys®, F. Hoffman-LaRoche, Copegus®, F. Hoffman-LaRoche |
| Sponsor | King Abdulaziz Medical City |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients (PHASE4)
- Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: